Compare OMH & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OMH | NEUP |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | 8 |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 23.8M |
| IPO Year | 2022 | N/A |
| Metric | OMH | NEUP |
|---|---|---|
| Price | $0.99 | $5.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 20.7K | ★ 36.1K |
| Earning Date | 05-12-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $3.65 |
| 52 Week High | $3.28 | $21.31 |
| Indicator | OMH | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 69.85 |
| Support Level | $0.98 | $3.85 |
| Resistance Level | $1.38 | $8.86 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 42.31 | 100.00 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.